Search
GlyT1 inhibitor
CatC inhibitor
Oxidase Inhibitor
Retinal Health
Human Pharma Clinical Pipeline Retinal Health therapeutic area
Aldosterone synthase inhibitor
Ion channel inhibitor
Ion channel inhibitor
KRAS multi-inhibitor
KRAS multi-inhibitor
Modified yersinia
Modified yersinia
Oxidase Inhibitor
Oxidase Inhibitor
SGLT2 inhibitor
Side Effects Reporting
Side Effects Reporting
Cat diabetes infographic with key facts and figures
786214027-001_BI_Speso_NS_Infographic_Unmet-Need_2024_cc04.pdf
Brigimadlin (BI 907828): MDM2-p53 antagonist | NSCLC
Brigimadlin (BI 907828): MDM2-p53 antagonist | NSCLC
Second generation STING agonist
Second generation STING agonist
BI 1291583: CatC Inhibitor
BI 1291583: CatC Inhibitor
Ion channel inhibitor
STING agonist (2nd generation)
KRAS multi-inhibitor
Modified yersinia
Semintra®
For the management of chronic kidney disease and hypertension in cats.
October 2024 Pipeline
Lysophospholipase inhibitor
Lysophospholipase inhibitor